Evidence map›Paper›PMID 42343091›Full record

ArticleBlood cancer journal2026

Efficacy of post-transplant brentuximab vedotin maintenance by pre-transplant disease status in relapsed/refractory classic Hodgkin lymphoma.

Sanjal H Desai, Susan M Geyer, Levi Pederson, Michael A Spinner, Veronika Bachanova, Andrew M Evens, Gaurav Goyal, Brad Kahl, Kathleen Dorritie, Jacques Azzi and 23 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Blood cancer journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

33 authors.

Sanjal H DesaiDivision of Hematology, Mayo Clinic, Rochester, MN, USA. desai171@umn.edu.ORCID http://orcid.org/0000-0002-7892-2625
Susan M GeyerDivision of Clinical Trials and Biostatistics, Mayo Clinic, Rochester, MN, USA.
Levi PedersonDivision of Clinical Trials and Biostatistics, Mayo Clinic, Rochester, MN, USA.ORCID http://orcid.org/0000-0001-5902-8882
Michael A SpinnerDivision of Oncology, Department of Medicine, Stanford University Medical Center, Stanford, CA, USA.
Veronika BachanovaDivision of Hematology, Oncology and Transplantation, Department of Medicine, University of Minnesota, Minneapolis, MN, USA.ORCID http://orcid.org/0000-0002-9325-432X
Andrew M EvensDivision of Blood Disorders, Rutgers Cancer Institute, New Brunswick, NJ, USA.
Gaurav GoyalDivision of Hematology-Oncology, University of Alabama at Birmingham, Birmingham, AL, USA.ORCID http://orcid.org/0000-0001-6148-5177
Brad KahlDivision of Hematology and Oncology, Washington University School of Medicine, St Louis, MO, USA.ORCID http://orcid.org/0000-0003-0459-6609
Kathleen DorritieDivision of Hematology-Oncology, UPMC Hillman Cancer Center, Pittsburg, PA, USA.
Jacques AzziDivision of Hematology & Medical Oncology, Icahn School of Medicine Mount Sinai, New York City, NY, USA.
Vaishalee P KenkreDivision of Hematology/Oncology/Palliative Care, University of Wisconsin, Madison, WI, USA.
Cheryl ChangDivision of Oncology, Department of Medicine, Stanford University Medical Center, Stanford, CA, USA.
Brendon FuscoDivision of Blood Disorders, Rutgers Cancer Institute, New Brunswick, NJ, USA.
Nuttavut SumransubDivision of Hematology, Oncology and Transplantation, Department of Medicine, University of Minnesota, Minneapolis, MN, USA.ORCID http://orcid.org/0000-0001-7456-0623
Haris HaticDivision of Hematology-Oncology, University of Alabama at Birmingham, Birmingham, AL, USA.
Raya SabaDivision of Hematology and Oncology, Washington University School of Medicine, St Louis, MO, USA.
Uroosa IbrahimDivision of Hematology & Medical Oncology, Icahn School of Medicine Mount Sinai, New York City, NY, USA.
Elyse I HarrisDivision of Hematology/Oncology/Palliative Care, University of Wisconsin, Madison, WI, USA.
Harsh ShahDivision of Hematology, Hunstman Cancer Institute, University of Utah, Salt Lake City, UT, USA.
Nina Wagner-JohnstonDepartment of Oncology, the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA.
Deepa JagadeeshCleveland Clinic Foundation, Cleveland, OH, USA.
Kristie A BlumDivision of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, GA, USA.
Catherine DiefenbachPerlmutter Cancer Center, NYU Grossman Medical School, New York City, NY, USA.
Siddharth IyengarDivision of Hematology, Hunstman Cancer Institute, University of Utah, Salt Lake City, UT, USA.
K C RappazzoDepartment of Oncology, the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA.
Firas BaidounCleveland Clinic Foundation, Cleveland, OH, USA.
Yun ChoiPerlmutter Cancer Center, NYU Grossman Medical School, New York City, NY, USA.
Ranjana H AdvaniDivision of Oncology, Department of Medicine, Stanford University Medical Center, Stanford, CA, USA.
Heidi MocikovaFakultni nemocnice Kralovske Vinohrady, Department of Haematology and Third Faculty of Medicine, Charles University, Prague, Czech Republic.
Alice SykorovaUniversity Hospital and Faculty of Medicine, 4th Department of Internal Medicine-Hematology, Hradec Kralove, Czech Republic.
Jozef MichalkaDepartment of Internal Medicine, Hematology and Oncology, Faculty of Medicine, University Hospital Brno, Masaryk University Brno, Brno, Czech Republic.
Vit Prochazka *Department of Haemato-Oncology, Faculty of Medicine and Dentistry Palacky University and University Hospital Olomouc, Olomouc, Czech Republic.ORCID http://orcid.org/0000-0002-9861-3117
Ivana N Micallef *Division of Hematology, Mayo Clinic, Rochester, MN, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Patients with classic Hodgkin lymphoma (cHL) with primary refractory disease, early relapse, or extranodal disease have a higher risk of relapse after salvage therapy and autologous stem cell transplant (ASCT). Post-ASCT brentuximab vedotin (BV) maintenance improved progression-free survival (PFS) in high-risk relapsed/refractory (R/R) cHL in the AETHERA trial, but subgroup analysis suggested that the benefit in patients transplanted in complete metabolic response (CMR) is unclear. In a large international real-world cohort, we assessed the efficacy of BV maintenance stratified by pre-ASCT metabolic response and by the number of clinical risk factors as defined in the AETHERA trial. Adult patients with R/R cHL who met AETHERA risk criteria were included. Utilizing propensity score analyses, PFS and OS were assessed overall and in subgroups of CMR (442 pts) and partial metabolic response (PMR, 249 pts). We observed that post-ASCT BV maintenance was associated with significantly higher PFS in the subgroup with PMR (5-year PFS: 59.6% vs 43.3% HR = 0.52, CI

Indexed as

Antineoplastic Agents, ImmunologicalBrentuximab VedotinHematopoietic Stem Cell TransplantationHodgkin DiseaseAdolescentAdultAgedFemaleHumansMaleMiddle AgedNeoplasm Recurrence, LocalSalvage TherapyYoung AdultAntineoplastic Agents, ImmunologicalBrentuximab Vedotin

Identifiers

PMID42343091
PMCPMC13554270

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.